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METHYSERGIDE INDUCED DEGRANULATION OF THE
BASOPHIL LEUKOCYTE IN MAN*
WALTER B. SHELLEY, M.D. AND SORREL S. RESNIK, M.D.
The disappearance of the circulating basophil
leukocyte in allergic reactions in man has been
described in urticaria, anaphylaxis (1), food
sensitivity and drug reactions such as penicillin
and novobiocin (2, 3). Moreover, in vitro de-
granulation of the basophil has been well studied
and documented in allergic states (4). The state
of the basophil in non-allergic conditions is less
well known, although recently the basophil has
been profiled for systemic medical conditions, as
well as for contact dermatitis (5, 6).
Although allergic drug reactions are associated
with degranulation and disappearance of the
basophil, less is known concerning the pharma-
cologic effect of drugs on this cell in man.
Steroids in high dosage cause a delayed baso-
penia (7). Histamine liberators, e.g. 48/SO,
are also known to lower the basophil count
(5). Estrogens and andrcgens were without
effect, whereas progesterone may cause a de-
crease in circulating basophils (9). Other hor-
mones were without pronounced effects (10).
In studies on rabbits, drugs have produced
variable responses (11).
The present study was undertaken as a
systematic survey of the effect of commonly
used drugs on the morphology and number of
circulating basophils in man. It was hoped to
find a drug capable of slowly and completely
degranulating the circulating basophils and
thereby depleting them of histamine. Such a
compound would have considerable prophy-
lactic value in the treatment of highly sensitized
individuals in whom the explosive degranu-
lation and release of histamine from the baso-
phil and associated mast cell have the potential
of shock and sudden death (12).
METHOD
Groups of five healthy Caucasian and Negro
adult males received medication orally in one
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dose. Ten cc of heparinized blood for absolute
basophil counts (ABC) by the chamber technic
were drawn before medication, and 4 hours, 24
hours, and 48 hours after medication. The basophil
count was performed immediately. Subjects were
not used on successive weeks.
Equipment
(1) WBC pipettes
(2) Eosinophil counting chamber (Spiers-
Levy)
(3) Diluting fluid
25 cc stock dye solution
7 cc hemolyzing solution
a) Stock dye solution
50 mgm Toluidine Blue
22 cc cf absolute ethyl alcohol
100 cc of 0.9% sodium chloride solution
b) Hemolyzing solution
Saturated solution of saponin (J. T.
Baker Chemical Co.) in 50 cc of ethyl
alcohol and 50 cc of distilled water.
This is a modification of Kovac's technic
(13). It was found that too little sapenin
would not hemolyze the red blood cells.
Seven cc of hemolyzing solution added
to 25 cc of stock solution gave excellent
visualization of the basophil. The diluting
fluid should be filtered daily and fresh
hemolyzing solution and diluting fluid be
used every 30 days.
Lichtgrun was also omitted from the
solution, as eosinophil morphology was
not recorded.
NOTE: Room temperature of 72° F. is
necessary. At higher temperatures, sa-
ponin in the diluting fluid precipitates in
the couuting chamber within minutes
preventing basophil determinations.
(4) Vacutainer®, B-D 3200 KA (Becton,
Dickinson and Company)
Procedure
(1) Draw blood to 1.0 mark in WBC pipette.
Add diluting fluid and continue drawing
to 11.0 mark. (1:10 dilution)
(2) Shake 30 seconds on pipette shaker, or 2
minutes manually.
(3) Discard first 4 drops from pipette.
(4) Fill each of the 4 chambers on counting
chamber.
(5) Place chamber in covered petri dish on
moistened filter paper. Let sit for 10 min-
utes to allow staining and settling of the
cells.
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TABLE I
Single Dose Drug Effect
(Data averaged for 5 subjects)
Zero 4 24 48Drug Dosage Hour Jirs. Hrs. Hrs.
No medication Degranulation 17% 27% 18% 13%
Absolute Basophil 48 52 41 54
Count (ABC)
Acetyl salicylic acid 30 gr Degranulation 22% 30% 28% 28%
ABC 37 42 45 41
Aqueous aspirin (Alka Seltzer®) 10 gr Degranulation 2% 10% 7% 5%
ABC 53 51 59 60
Aminopterin 0.5 mgm Degranulation 31% 31% 30% 17%
ABC 67 64 55 62
Calcium lactate (placebo) 10 gr Degranulation 6% 8% 5% 3%
ABC 33 30 25 26
Chiordiazepoxide hydrochloride 20 mgm Degranulation 28% 37% 38% 35%
(Librium®) ABC 32 34 35 35
Chioramphenicol (Chloromy- 500 mgm Degranulation 11% 20% 26% 23%
cetin®) ABC 61 60 60 59
Chioroquine (Aralen®) 500 mgm Degranulation 15% 47% 56% 53%
ABC 67 66 58 59
Dexchlorpheniramine maleate 6 mgm Degranulation 13% 14% 19% 9%
(Polaramine®) ABC 38 43 45 45
Dextroamphetamine (Dexe- 15 mgm Degranulation 29% 43% 44% 39%
drine®) ABC 57 60 59 66
Ethinyl estradiol (Estinyl®) 0.5 mgm Degranulation 19% 23% 30% 31%
ABC 37 46 49 39
Griseofulvin (Grisactin®) 500 mgm Degranulation 14% 22% 43% 48%
ABC 65 45 47 42
Guanethidine (Ismelin®) 20 mgm Degranulation 20% 20% 25% 29%
ABC 51 62 59 53
Isoniazid 1 tablet Degranulation 17% 17% 8% 17%
ABC 60 53 54 50
Lactose (placebo) 10 gr Degranulation 8% 25% 22% 14%
ABC 48 43 47 58
Liothyronine (Cytomel®) 25 meg Degranulation 14% 9% 15% 19%
ABC 34 40 35 31
Meprobamate (Miltown®) 800 mgm Degranulation 14% 17% 25% 19%
ABC 46 37 39 46
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TABLE I—Continued
Drug Dosage ZeroHour
4
Hrs.
24
SIrs.
45
SIrs.
Methysergide maleate (San-
sert®)
4 mgm Degranulation
ABC
16%
31
32%
25
65%
32
69%
35
Norethindrone neetate (Norlu-
tate®)
10 mgm Degranulation
ABC
16%
60
39%
56
50%
56
55%
64
Novobiocin sodium (Albamy-
cm®)
250 mgm Degranulation
ABC
14%
38
7%
36
18%
32
30%
29
Phenylbutazone (Butazolidin®) 100 mgm Degranulation
ABC
24%
53
30%
56
30%
45
25%
51
Polymixin B sulfate 50 mgm Degranulation
ABC
9%
38
13%
44
10%
32
3%
43
Reserpine (Serpasil®) 2 mgm Degranulation
ABC
31%
32
28%
28
20%
27
19%
29
Triameinolone (Aristoeort®) 4 mgm Degranulation
ABC
12%
39
48%
37
83%
34
42%
36
Trimethadione (Tridione®) 300 mgm Degranulation
ABC
21%
49
36%
51
35%
51
39%
50
Vitamin A (Aquasol A®) 50,000 units Degranulation
ABC
29%
48
31%
50
36%
47
20%
44
(6) Read under high power (430 X). Count
every square in each of the four chambers.
(7) Total the 4 counts, multiply this number
by the correction factor 5 and then di-
vide by the factor 4 (number of cham-
bers). Report results per cu mm of blood.
The basophil count is read with the bright light
of A-O Spencer microscope at 430 )< (eyepieces
10 X, objective 43 X) using a didymium filter(Corning Class, CS 160). Total time from blood-
letting to completion of count is less than thirty
minutes. Basophil morphology, as well as num-
ber, is recorded.
Normal basophils and degranulated basophils
are classified. The percentage of basophil degran-
ulation is determined by the per cent of the baso-
phils which show degranulation.
Classification of Besophils
To facilitate a standard means of classification
two categories are used: normal basophils and
degranulated basophils. Normal cells have intense
pink to purple stain, numerous small, reddish-
purple granules located centrally and distinct
cell outline.
Abnormal cells have light or faded pink stain,
only two to five granules centrally or peripherally
with central clearing. The granules not only de-
crease in number but become swollen as well.
Vacuoles can be seen centrally and cellular outline
becomes indistinct with cell shrinkage. Degranula-
tion may be seen with granules extruding from
the cell.
RESULTS AND DISCUSSION
Single Dose Drug Effect (Table I)
In repeated basophil counts of treated and
untreated individuals, the absolute number of
basophils remained relatively constant. No
medication was found capable of simulating
anaphylactic or acute urticarial reaction during
which few circulating basophils remain.
It was possible, however, to induce striking
cytologic changes in the basophil. These changes
were noted in the cells as lessening in staining
quality, reduced number of intracellular gran-
ules, centrifugal gathering of granules rather
than central clumping, appearance of vacuoles
within the cell, and even extrusion of granules
when the basophil has ruptured. An arbitrary
value of 0—30% basophil degranulation was con-
sidered normal. Above 30% was considered an
abnormal response. The percentage of basophil
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Fio. 1. Chemical structure of mcthysergide
maleate (Sansert®, Deseril®).
degranulation following a single dose of medi-
cation can be seen in Table I. Groups treated
with placebo medications (calcium lactate and
lactose), as well as one group with no medica-
tion, showed a normal basophil picture over the
entire 48 hour period. Most drugs tested com-
pared closely with these findings. In 26 test
situations only 5 were seen to induce noticeable
morphologic change in the basophil. These were
chloroquin, dextroamphetaminc, methysergide
maleatc, norethindronc and triamcinolonc.
Our findings of dcgranulation with triamcino-
lone agrees well with recent work (7). This
may explain in part the beneficial results of
steroids in reducing or preventing symptoms
asssociatcd with drug allergy. One might also
consider that the known anti-inflammatory
effect of chloroquin is also related to this
degranulation property. The effect of dextro-
amphetamine was unexpected and might well
be studied further. The results with the pro-
gestational compound, norethindrone, are in
agreement with the previous observation (9)
that progesterone may cause some basopenia.
Degranulation by methyscrgide was more
marked than other drugs (Fig. 2, 3).
Long-Term Drug Effect (Table II)
Having shown some effect with a single dose,
the question arose: "Would long-term drug
therapy with maintained high blood levels be
more damaging to the basophil?" To attempt
to answer this question, 5 drugs were studied.
Two of these were shown in Table I to have
no effect—dexchlorpheniramine and chloram-
phcnicol. The other 3—mcthyscrgide, norcthin-
TABLE II
Long-term Drug Effect
(Data averaged for 5 subjects)
Drug Dosage Zero Hour 4 nra.
Days
—
1 2 3 4 5 6 13
Chloramphenicol (Chlor-
omycetin®)
250 mgm four times daily
Degranulation
Absolute Basophil Count
(ABC)
5%
34
2%
32
15%
40
20%
39
21%
38
4%
41
6%
37
6%
34
9%
30
Dexchlorpheniramine
maleate (Polara-
mine®)
8 mgm twice daily
Degranulation
ABC
9%
41
10%
50
24%
47
37%
49
36%
47
11%
47
18%
41
33%
41
18%
44
Methysergide maleate
(Sansert®)
2 mgm three times daily
Degranulation
ABC
3%
48
26%
50
46%
49
65%
53
93%
52
93%
56
87%
51
83%
56
83%
58
Norethindrone acetate
(Norlutate®)
5 mgm twice daily
Degranulation
ABC
3%
33
38%
41
33%
33
66%
39
58%
42
47%
37
36%
33
25%
36
32%
32
Triamcinolone (Aristo-
cort®)
4 mgm four times daily
Degranulation
ABC
4%
28
19%
26
52%
28
36%
27
34%
26
55%
28
42%
32
29%
27
26%
23
G4*.
UI
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drone and triamcinolone—wcre effective in pro-
ducing some degree of degranulation after 4
hours and 24 hours (Table I), and might repre-
sent drugs capable of inducing 100% basophil
degranulation and basopenia.
Again methysergide (Fig. 1) showed pro-
nounced degranulation, more dramatic than
any of the other medications tested. Within 24
hours 46% degranulation had occurred, later
reaching a peak level of 83—93% degranulation.
Chloramphcnicol and dexchlorpheniramine had
no significant degranulation effect. Norethin-
drone and triamcinolone showed a mild dc-
granulating effect, but this was not sustained.
There was no basopenic response concomitant
with degranulation.
Fin. 2. Appearance of circulating basophil leukocytes of Subject 2 in counting chamber. Blood was
drawn 4 hours after a single, oral dose of placebo. (Magnification 1750 X)
FIG. 3. Appearance of circulating basophil leukocytes of the same Subject 2, 4 hours after a single,
oral dose of 4 mgm Methyscrgide. (Magnification 1750 X)
0
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Further Studies with Met hysergide
Maleate (Sansert) (Fig. 4, 5)
To further study methysergide, a new group
of subjects was given the drug in increasing
daily dosage. Side effects were lessened con-
siderably by administration with food. Never-
theless, transient changes were noted by 4 of 5
subjects. On day 5, the circulating basophils
became smaller. Figure 4 reflects per cent de-
granulation reaching a maximum at the peak
dose of 12 mg daily and falling sharply as the
dose was decreased on day 15. We were unable
to cause 100% degranulation. Apparently ma-
ture basophils can be degranulated but im-
mature basophils in their "green" state are less
susceptible to degranulation. Slight change was
noted in the absolute number of basophils
(Fig. 5). In instances a substantial increase in
the absolute count was seen. This can be ex-
plained by a rapid outpour of new immature
basophils from the bone marrow.
Methysergide is well known to produce side
effects (15). Employing a low dosage schedule
of 2 mg twice a day with meals and increasing
gradually, side effects can be lessened, but not
completely eliminated. Certain subjects are
more susceptible, and in these one sees nausea,
paresthesias, leg cramps, flushing and vertigo.
In our series, these were transient, lasting only
several hours.
Methysergide disruption of basophil mor-
phology has been more dramatic and more
rapid than any drug in our series. Many cells
were seen extruding granules in a spray like
pattern. This relatively new compound is
highly effective for the prophylactic treatment
of vascular headache, such as migraine and
cluster headache (histamine cephalgia) (16).
It has not been effective in management of
the acute attack. Chemically, it is 1-methyl-D-
lysergic acid butanolamide, a derivative of
lysergic acid and a potent serotonin antagonist
(Fig. 1). It has been shown to block both
serotonin dilatation and active components of
reflex vascular dilatation (17). We have shown
an effect on the basophil and we may assume
the same effect on the mast cell, causing a
gradual, slow degranulation. Certainly, in keep-
ing with this view, Wolff and his group (16)
have shown that methysergide (TJML-491) can
produce a marked reduction in the inflamma-
tory response of human skin.
0 5 10 IS
14H6—t8*-10-+-l2H
Dosage In mgm/day
20 25 3ODQys
FIG. 4. Methysergide-induced degranulation: increase in percentage of basophils showing degranu-
latioa during administration of methysergide daily with meals. Dose increase caused gradual increase
in degranulation. Note sudden decrease in degranulation response as medication is withdrawn. The
graph gives data averaged for 5 subjects.
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Fm. 5. Daily methysergide administration had no
Data represents average for 5 subjects.
We suspect that at least part of the known
benefits of methysergide in the prophylactic
treatment of migraine and histaminic head-
aches results from its effect on the basophil.
It would appear that the basophil-mast cell
plays a significant role in the migraine syn-
drome. Triggered by various stimuli it may
unload its histamine and heparin. In support of
such a hypothesis, the blood coagulability has
been shown to be sharply reduced during
migraine attacks (18). The role of the basophil,
as a source of bound histamine, is even more
evident in histamine headache. In this instance
numerous antigens may trigger basophil and
mast cell degranulation with a subsequent
histamine headache (19).
We feel that methyscrgide offers the mi-
graine patient help by exhausting or depleting
the basophil-mast cell stores of histamine. The
continuous daily maintenance dosage is neces-
sary to keep this cell system effete. As long as
the basophil-mast cell is unable to respond to
stress or allergens, the migraine attacks are
lessened or eliminated.
By analogy, we feel that methysergide may
offer the highly allergic individual relative pro-
tection from allergen triggered explosive release
of basophil-mast cell stores of histamine. Some
20 25 30 Days
appreciable effect on the absolute basopbil count.
unpublished animal studies support this (20).
For example, methysergide in a single dose of
50 mg/kg intraperitoneally protected 6 of 8 egg
albumin sensitized guinea pigs from fatal
anaphylactic shock.
The possibility that regular long-term daily
dosage of methysergide will afford protection to
patients highly sensitized to bee stings, penicil-
lin, radio-opaque dyes, or food allergens de-
serves appropriate study.
sUMMARY
Twenty-five drugs were studied for effects on
the morphology and number of circulating
basophil leucocytes.
Five of the drugs, triamcinolone, chloroquin,
methysergide, dextroamphetamine, and nor-
ethindrone, were found to canse significant de-
granulation of the basophils. No effect on the
absolute basophil count was noted.
Methysergide proved to be the most effec-
tive of the five drugs. In dosage of from 2 to 12
mgm a day, it induced striking basophil
changes.
It appears possible that the basophil-mast
cell plays a significant role in the etiology of
migraine and histamine headaches. Methy-
sergide is viewed as preventing attacks by
E
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depleting the basophils of their histamine-
heparin granules.
It is suggested that methysergide be consid-
ered as a means of safe yet rapid "pharma-
cologic hyposensitization" of the highly allergic
individual.
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